World-Class Biologics

Medicines for Global Markets

OUR VISION

To improve global healthcare by increasing the availability of biotechnology medicines.

OUR MISSION

To develop and manufacture high quality biologics at affordable prices through manufacturing innovation, state-of-the-art technologies to ensure all patient needs are addressed and met and to promote and accelerate the success of our clients.

OUR VALUES

At Eden Biologics, we value and foster an environment for continuous learning, encourage open communication and team building, building trust with our clients, and emphasize the importance of cGMP with tight CMC strategies to produce the highest quality biologics.

Eden Biologics, Inc. Announces the Completion of the Sale of CDMO Business Assets

July 6, 2022

To Eden Biologics Investors, Partners, Colleagues and Friends: I would like to take this opportunity to inform our shareholders that our CDMO Business Unit has been acquired by Bora Pharmaceuticals Co., LTD. Bora, effective as of July 1, 2022.

Eden Biologics Introduces New Chief Executive Officer, Dr. Steve Lee

September 21, 2021

Eden Biologics, Inc., a leading global biotechnology company based in Hsinchu, Taiwan, announced on September 1st, the appointment of Dr. Steve Lee, an accomplished biotech executive with broad experience and entrepreneurial leadership, as the new CEO and Director of the Board, effective immediately.

Eden Biologics’ Leading Biosimilar Program Receives Phase 3 Approval in Europe

August 31, 2021

We’ve once again achieved a huge corporate milestone and are excited to share the great news with all of you! Our EB-CLIN-1001-03 Phase 3 Clinical Trial for our leading Biosimilar Program EB1001, received approval from Hungary’s National Institute of Pharmacy and Nutrition (OGYÉI), as well as the Ethics Committee!

Eden Biologics Statement

July 9, 2021

Earlier this week, the United States Department of Justice announced that it has filed criminal charges against Racho Jordanov and Rose Lin, former employees of JHL Biotech (the predecessor to Eden Biologics), relating to alleged theft of trade secrets from Genentech.

Eden Biologics Proudly Announces Dr. Scott Liu as Board Member

March 15, 2021

Eden Biologics is honored to announce the addition of Dr. Scott Liu as a member of the Eden Board of Directors.

Eden Biologics Anticipates Initiation of Global Phase 3 in 2021 H2 for Its Denosumab Biosimilar

February 25, 2021

Eden Biologics, Inc., a global frontrunner in biological drug development and manufacturing platform technologies, today announced completion of enrollment for their Phase 1 comparative PK Clinical Trial (JHL-CLIN-1266-01) of Eden’s lead product candidate EB1001

World-Class Biologics

Medicines for Global Markets

OUR VISION

OUR MISSION

OUR VALUES

Eden Biologics, Inc. Announces the Completion of the Sale of CDMO Business Assets

Eden Biologics Introduces New Chief Executive Officer, Dr. Steve Lee

Eden Biologics’ Leading Biosimilar Program Receives Phase 3 Approval in Europe

Eden Biologics Statement

Eden Biologics Proudly Announces Dr. Scott Liu as Board Member

Eden Biologics Anticipates Initiation of Global Phase 3 in 2021 H2 for Its Denosumab Biosimilar

JHL Biotech Officially Changes Name to EDEN Biologics

Q-Sera Pty Ltd and JHL Biotech, Inc. Announce a Strategic Collaboration

First Subjects Dosed in Australian Phase I Clinical Study of a Denosumab Biosimilar

OUR PARTNERS & INVESTORS

EDEN BIOLOGICS

TEAM & NEWS

CONTACT INFO